文献速递前列腺增生与排尿功能障碍

良性前列腺增生药物治疗与心力衰竭风险:一项基于人群的研究

Cardiac Failure Associated with Medical Therapy of Benign Prostatic Hyperplasia: A Population Based Study.
PubMed 文献 · J Urol · 2021-02-24

该研究基于人群行政数据库,纳入2005至2015年间诊断良性前列腺增生的66岁以上男性175,201例,评估5α还原酶抑制剂和/或α受体阻滞剂暴露与新发心力衰竭的关联。结果显示,与未用药相比,单用或联用这两类药物均与心力衰竭诊断风险升高相关,其中非选择性α受体阻滞剂风险最高。

要点

  • 单用α受体阻滞剂的心衰风险最高(HR 1.22),联合治疗次之(HR 1.16),单用5α还原酶抑制剂最低(HR 1.09)。
  • 非选择性α受体阻滞剂的心衰风险高于选择性α受体阻滞剂(HR 1.08)。
  • 临床需关注BPH长期药物治疗患者的心衰风险,尤其是非选择性α受体阻滞剂使用者。

核心结论

  • 在常规诊疗中,BPH患者暴露于5α还原酶抑制剂和α受体阻滞剂(单用或联用)与新发心力衰竭诊断风险升高相关。
  • 非选择性α受体阻滞剂暴露者的心衰风险最高。

研究设计与样本

  • 基于人群的行政数据库研究,纳入2005至2015年间所有诊断BPH的66岁以上男性175,201例。
  • 按5α还原酶抑制剂和/或α受体阻滞剂暴露分组,采用竞争风险模型分析新发心力衰竭。

主要发现

  • 数据集包括175,201例BPH男性,其中5α还原酶抑制剂暴露8,339例,α受体阻滞剂暴露55,383例,联合治疗暴露41,491例。
  • 与未用药相比,单用α受体阻滞剂的心衰风险HR 1.22(95%CI 1.18-1.26)。
  • 联合α受体阻滞剂/5α还原酶抑制剂的心衰风险HR 1.16(95%CI 1.12-1.21)。
  • 单用5α还原酶抑制剂的心衰风险HR 1.09(95%CI 1.02-1.17)。
  • 非选择性α受体阻滞剂的心衰风险高于选择性α受体阻滞剂(HR 1.08;95%CI 1.00-1.17)。

关键数值与推荐

  • 心衰风险比较以未用药为参照,采用竞争风险模型。
  • 解释变量包括暴露阈值、剂型、年龄及与心脏病相关的合并症。

临床怎么用

  • 对BPH患者长期药物治疗时,应评估心衰风险,尤其使用非选择性α受体阻滞剂者。
  • 选择α受体阻滞剂时可优先考虑选择性α受体阻滞剂以降低心衰风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Increased risk of cardiac failure with α-blockers in hypertension studies and 5-alpha reductase inhibitors in prostate studies have raised safety concerns for long term management of benign prostatic hyperplasia. The objective of this study was to determine if these medications are associated with an increased risk of cardiac failure in routine care. MATERIALS AND METHODS: This population based study used administrative databases including all men over 66 with a diagnosis of benign prostatic hyperplasia between 2005 and 2015. Men were categorized based on 5-alpha reductase inhibitor exposure and/or α-blocker exposure with a primary outcome of new cardiac failure utilizing competing risk models. Explanatory variables examined included exposure thresholds, formulations, age, and comorbidities associated with cardiac disease. RESULTS: The data set included 175,201 men with a benign prostatic hyperplasia diagnosis with 8,339, 55,383, and 41,491 exposed to 5-alpha reductase inhibitor, α-blocker and combination therapy, respectively. Men treated with 5-alpha reductase inhibitor and α-blocker, alone or in combination, had a statistically increased risk of being diagnosed with cardiac failure compared to no medication use. Cardiac failure risk was highest for α-blockers alone (HR 1.22; 95% CI 1.18-1.26), intermediate for combination α-blockers/5-alpha reductase inhibitors (HR 1.16; 95% CI 1.12-1.21) and lowest for 5-alpha reductase inhibitors alone (HR 1.09; 95% CI 1.02-1.17). Nonselective α-blocker had a higher risk of cardiac failure than selective α-blockers (HR 1.08; 95% CI 1.00-1.17). CONCLUSIONS: In routine care, men with a benign prostatic hyperplasia diagnosis and exposed to both 5-alpha reductase inhibitor and α-blocker therapy had an increased association with cardiac failure, with the highest risk for men exposed to nonselective α-blockers.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Lusty A, Siemens DR, Tohidi M, et al. Cardiac Failure Associated with Medical Therapy of Benign Prostatic Hyperplasia: A Population Based Study. J Urol. 2021. PMID: 33616451. doi:10.1097/JU.0000000000001561

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。